Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure Inc has demonstrated robust financial growth, with pain management revenue reaching $22.6 million, reflecting a year-over-year increase of 27.3%, and Appendage Management revenue of $45.5 million, up 12.8% year-over-year. The company's total revenue for the fourth quarter of 2025 was reported at $140.5 million, marking a 13.1% increase year-over-year and indicating strong performance across its global operations. Furthermore, potential upside drivers include anticipated stronger sales from new product launches and improving margins, which may enhance profitability and free cash flow in the future.

Bears say

AtriCure Inc's recent financial performance indicates challenges in key revenue segments, particularly a significant decline in its Minimally Invasive Ablation product line, with revenue dropping by 24.3% year-over-year, suggesting ongoing struggles with market acceptance. Additionally, the growth rate for US Appendage Management has notably decreased, falling from 21.7% in the previous quarter to 11.0% in the current quarter, raising concerns about the sustainability of future revenue growth. Furthermore, the risks outlined include potential market share loss to new competitors, slower margin improvement, and the impact of rising healthcare costs, which could hamper overall financial stability and profitability.

AtriCure (ATRC) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 8 analysts, AtriCure (ATRC) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.